Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience

Abstract

Treatment with SOF (400 mg) plus DCV (60 mg), with or without RBV (800-1000 mg) for 12 or 24 weeks, was effective and well tolerated in chronic hepatitis C genotype 4 patients. SVR rates were higher for patients with no cirrhosis. Addition of RBV has benefit only in treatment-experienced group receiving 24 weeks.

Efficacy and Adverse Effects of Sofosbuvir plus Daclatasvir Therapy in Chronic HCV Patients in Sharkia Governorate, Egypt

“…In addition to the excellent antiviral activity (100% SVR) and accepted safety profile (mild adverse events) of Daclatasvir/sofosbuvir regimen in treatment of our cohort with HCV, the biochemical parameters and clinical items were also improved and this noticed in improvements of the Child scores reported after the end of treatment. These improvements of biochemical and clinical parameters were also reported by other authors from the local Egyptian community [20][21][22] and by international authors [23].…”

Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy

“…Table 1 shows the demographic data of patients revealing that, 122 patients were males and 78 patients were female with a mean age of 56 years. Table 2 shows the laboratory data of the studied patients, who had a median viral load of 3.59×10 5…”

Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt

“…The estimated rates of HCV infection in Egypt is around 14.7%, and the predominant HCV GT is GT4, where GT4a, GT4b, GT1 and GT3 represent 63, 30, 6 and 1% of cases, respectively [1]. Recently, the results of treatment with combinations of direct-acting antivirals (DAAs) for HCV GT4 Egyptian patients have been reported [2][3][4][5][6]. Almost all of these regimens could lead to more than 95% or more than 90% SVR rates, respectively, in the following patients: ''easy-to-treat'' patients who were treatment-naïve and did not have cirrhosis but had compensated liver biochemical parameters or ''difficult-to-treat'' patients who had previously failed interferon therapy with or without DAAs or an interferon-free combination, regardless of fibrosis stage, and had cirrhosis.…”

“…Shiha et al [2] investigated the efficacy and safety of 12 or 24 weeks of 400 mg/day SOF plus 60 mg/day DCV, with or without 800-1000 mg/day ribavirin, in HCV GT4 Egyptian patients. Although this was an open-label observational study, it includes a total 1168 patients: 385 patients with cirrhosis and 1063 treatment-naïve patients [2].…”

“…Shiha et al [2] investigated the efficacy and safety of 12 or 24 weeks of 400 mg/day SOF plus 60 mg/day DCV, with or without 800-1000 mg/day ribavirin, in HCV GT4 Egyptian patients. Although this was an open-label observational study, it includes a total 1168 patients: 385 patients with cirrhosis and 1063 treatment-naïve patients [2]. The authors observed rates of 96 and 93% SVR at 12 weeks (SVR12), respectively, with 12-and 24-week combinations of SOF/DCV with or without ribavirin, both in naïve and treatment-experienced patients with or without cirrhosis.…”